https://www.elicera.com https://www.elicera.com/immuno-oncology https://www.elicera.com/about-elicera https://www.elicera.com/technology https://www.elicera.com/pipeline https://www.elicera.com/news https://www.elicera.com/sv/om-elicera https://www.elicera.com/sv/immunonkologi https://www.elicera.com/sv/teknologi https://www.elicera.com/sv/pipeline https://www.elicera.com/sv/nyheter https://www.elicera.com/sv/home https://www.elicera.com/investors-2/press-releases https://www.elicera.com/sv/investerare/pressmeddelanden https://www.elicera.com/investors-2/board https://www.elicera.com/investors-2/management https://www.elicera.com/investors-2/articles-of-association https://www.elicera.com/investors-2/general-meeting https://www.elicera.com/investors-2/financial-reports https://www.elicera.com/investors-2/financial-calendar https://www.elicera.com/investors https://www.elicera.com/contact https://www.elicera.com/sv/investerare/bolagsordning https://www.elicera.com/sv/investerare/bolagsstamma https://www.elicera.com/sv/investerare/styrelse https://www.elicera.com/sv/investerare/ledning https://www.elicera.com/sv/investerare/finansiella-rapporter https://www.elicera.com/sv/investerare/finansiell-kalender https://www.elicera.com/sv/kontakt https://www.elicera.com/sv/investerare https://www.elicera.com/sv/investerare/aktien https://www.elicera.com/investors-2/the-share https://www.elicera.com/sv/investerare/emissioner/marknadsnotering-juni-2021 https://www.elicera.com/investors-2/share-issues/ipo https://www.elicera.com/events https://www.elicera.com/sv/events https://www.elicera.com/investors-2/auditor https://www.elicera.com/investors-2/certified-adviser https://www.elicera.com/sv/investerare/revisor https://www.elicera.com/sv/investerare/certified-adviser https://www.elicera.com/investors-2/analyst-coverage https://www.elicera.com/sv/investerare/analys https://www.elicera.com/itank https://www.elicera.com/sv/investerare/emissioner/foretradesemission-2024 https://www.elicera.com/sv/investerare/emissioner-2 https://www.elicera.com/investors-2/share-issues-2 https://www.elicera.com/sv/investerare/emissioner/teckningsoption-to2 https://www.elicera.com/sv/nar-dagens-cancerbehandlingar-inte-racker-utvecklas-nya-angreppssatt https://www.elicera.com/sv/investerare/emissioner/foretradesemission-2026 https://www.elicera.com/sv/elicera-oppnar-for-teckning https://www.elicera.com/sv-team-se/agneta-edberg https://www.elicera.com/sv-team-se/anna-koptina-gultekin https://www.elicera.com/sv-team-se/christina-herder https://www.elicera.com/sv-team-se/di-yu https://www.elicera.com/sv-team-se/gunilla-enblad https://www.elicera.com/sv-team-se/ingvar-karlsson https://www.elicera.com/sv-team-se/jamal-el-mosleh https://www.elicera.com/sv-team-se/magnus-essand https://www.elicera.com/sv-team-se/magnus-essand-2 https://www.elicera.com/sv-team-se/margareth-jorvid https://www.elicera.com/sv-team-se/sharon-longhurst https://www.elicera.com/sv-team-se/sujata-bhoi https://www.elicera.com/team-members-en/agneta-edberg https://www.elicera.com/team-members-en/anna-koptina-gultekin https://www.elicera.com/team-members-en/christina-herder https://www.elicera.com/team-members-en/di-yu https://www.elicera.com/team-members-en/gunilla-enblad https://www.elicera.com/team-members-en/ingvar-karlsson https://www.elicera.com/team-members-en/jamal-el-mosleh https://www.elicera.com/team-members-en/magnus-essand https://www.elicera.com/team-members-en/magnus-essand-2 https://www.elicera.com/team-members-en/margareth-jorvid https://www.elicera.com/team-members-en/sharon-longhurst https://www.elicera.com/team-members-en/sujata-bhoi https://www.elicera.com/press-releases/article-in-forskning-och-framsteg https://www.elicera.com/press-releases/biostock-makes-a-video-interview-with-cso-professor-magnus-essand-on-the-itank-publication https://www.elicera.com/press-releases/biostock-writes-about-elicera-and-car-t-cells https://www.elicera.com/press-releases/board-members-and-the-executive-management-exercise-warrants-of-series-to2-in-elicera-therapeutics https://www.elicera.com/press-releases/ceo-interview-by-nyhetsbyran-direkt https://www.elicera.com/press-releases/company-presentation-at-aktiedagen-goteborg https://www.elicera.com/press-releases/correction-board-members-and-the-executive-management-exercise-warrants-of-series-to2-in-elicera-therapeutics https://www.elicera.com/press-releases/correction-elicera-therapeutics-ab-publ-changes-certified-adviser-and-liquidity-provider-to-dnb-carnegie-investment-bank-ab-publ https://www.elicera.com/press-releases/daiy-mail-writes-about-elicera https://www.elicera.com/press-releases/di-yu-is-awarded-the-goran-gustavsson-prize https://www.elicera.com/press-releases/elicera-announces-appointment-of-atmp-specialist-karin-hoogendoorn-to-the-board https://www.elicera.com/press-releases/elicera-clarifies-status-of-the-itank-platform-patent-application-in-the-u-s https://www.elicera.com/press-releases/elicera-enters-agreement-with-prominent-us-cancer-center-to-evaluate-the-use-of-itank-in-t-cell-receptor-therapies https://www.elicera.com/press-releases/elicera-featured-in-life-science-swedens-perspective-on-car-t-cell-therapies https://www.elicera.com/press-releases/elicera-in-nordic-life-science-vinnova-grant https://www.elicera.com/press-releases/elicera-invites-to-investor-meetings-on-february-28-th-and-29-th-2024 https://www.elicera.com/press-releases/elicera-recruits-cfo https://www.elicera.com/press-releases/elicera-reports-active-lymphoma-eliminated-in-four-out-of-six-patients-in-the-first-two-low-dose-cohorts-of-the-carma-study-with-itank-armed-car-t-cell-therapy https://www.elicera.com/press-releases/elicera-reports-active-lymphoma-eliminated-in-two-out-of-three-patients-in-the-first-cohort-of-the-carma-study-with-itank-armed-car-t-cell-therapy https://www.elicera.com/press-releases/elicera-s-board-of-directors-proposes-a-rights-issue-of-units-of-approximately-sek-64-million https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-changes-certified-adviser-and-liquidity-provider-to-dnb-carnegie-investment-bank-ab-publ https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-1-january---30-june-2025 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-1-january---30-september-2025 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-1-january---31-march-2025 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january---30-june-2024 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january---30-september-2024 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january---31-march-2024 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january---31-march-2026 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january-30-june-2022 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january-30-june-2023 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january-30-june-2023-f5427 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january-30-september-2021 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january-30-september-2022 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january-31-december-2021 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january-31-march-2022 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-interim-report-1-january-31-march-2023 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-year-end-1-january---31-december-2025 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-year-end-report-1-january---31-december-2023 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-year-end-report-1-january---31-december-2024 https://www.elicera.com/press-releases/elicera-therapeutics-ab-publ-year-end-report-1-january-31-december-2022 https://www.elicera.com/press-releases/elicera-therapeutics-abstract-on-the-itank-platform-s-potential-to-enhance-car-t-cell-treatment-of-solid-tumors-accepted-for-presentation-at-isct-2024 https://www.elicera.com/press-releases/elicera-therapeutics-announces-abstract-acceptance-at-isct-2026-dublin-complete-metabolic-response-achieved-in-four-of-six-patients-with-itank-armed-elc-301-in-carma-lymphoma-study https://www.elicera.com/press-releases/elicera-therapeutics-announces-final-data-from-its-phase-i-iia-trial-demonstrating-a-favorable-safety-profile-and-promising-efficacy-signals-of-oncolytic-virus-elc-100-in-neuroendocrine-tumors https://www.elicera.com/press-releases/elicera-therapeutics-announces-outcome-in-rights-issue https://www.elicera.com/press-releases/elicera-therapeutics-announces-participation-in-several-industry-and-investor-meetings-in-october-and-november https://www.elicera.com/press-releases/elicera-therapeutics-announces-participation-in-several-industry-and-partnering-conferences https://www.elicera.com/press-releases/elicera-therapeutics-announces-swedish-cancer-society-s-senior-investigator-award-to-chief-development-officer-di-yu https://www.elicera.com/press-releases/elicera-therapeutics-announces-that-the-swedish-cancer-society-has-awarded-professor-magnus-essand-at-uppsala-university-a-grant-of-7-5-million-sek-for-car-t-cell-research https://www.elicera.com/press-releases/elicera-therapeutics-announces-the-last-day-of-trading-in-btu-and-the-first-day-of-trading-in-warrants-of-series-to2 https://www.elicera.com/press-releases/elicera-therapeutics-announces-the-next-safety-update-in-the-phase-i-ii-study-with-elc-100 https://www.elicera.com/press-releases/elicera-therapeutics-appoints-professor-gunilla-enblad-key-opinion-leader-within-the-fields-of-car-t-cells-and-b-cell-lymphoma-as-scientific-advisor https://www.elicera.com/press-releases/elicera-therapeutics-board-and-management-buy-shares https://www.elicera.com/press-releases/elicera-therapeutics-carries-out-a-rights-issue-of-approximately-sek-73-million https://www.elicera.com/press-releases/elicera-therapeutics-ceo-sells-a-small-portion-of-his-shareholding---remains-a-long-term-major-shareholder-with-strong-confidence-in-the-company-s-future https://www.elicera.com/press-releases/elicera-therapeutics-changes-certified-adviser-and-liquidity-provider-to-carnegie-investment-bank-ab-publ https://www.elicera.com/press-releases/elicera-therapeutics-changes-certified-adviser-and-liquidity-provider-to-mangold-fondkommission-ab https://www.elicera.com/press-releases/elicera-therapeutics-chief-scientific-officer-invited-to-speak-at-the-swedish-cancer-research-meeting-2025-on-may-22 https://www.elicera.com/press-releases/elicera-therapeutics-chief-scientific-officer-magnus-essand-named-cancer-researcher-of-the-year-2026-by-the-swedish-cancer-society-cancerfonden https://www.elicera.com/press-releases/elicera-therapeutics-chief-scientific-officer-professor-magnus-essand-to-present-at-swecarnet-s-educational-day-2022 https://www.elicera.com/press-releases/elicera-therapeutics-co-founder-magnus-essand-invited-to-present-the-company-s-car-t-cell-projects-at-the-world-s-largest-cancer-immunotherapy-conference-cicon https://www.elicera.com/press-releases/elicera-therapeutics-co-founder-receives-a-grant-totalling-4-8-msek-from-the-swedish-childhood-cancer-fund-to-support-car-t-cell-research https://www.elicera.com/press-releases/elicera-therapeutics-co-founders-receive-additional-grants-totalling-7-65-msek-from-the-swedish-cancer-society-to-support-car-t-research https://www.elicera.com/press-releases/elicera-therapeutics-completes-oversubscribed-share-issue-and-launches-unique-immuno-oncology-company-with-focus-on-car-t-cells-and-oncolytic-viruses https://www.elicera.com/press-releases/elicera-therapeutics-completes-oversubscribed-share-issue-and-secures-13-2-msek-in-financing https://www.elicera.com/press-releases/elicera-therapeutics-continues-phase-i-iia-carma-study-with-car-t-cell-therapy-as-planned-following-safety-committee-s-assessment-in-cohort-2 https://www.elicera.com/press-releases/elicera-therapeutics-continues-phase-i-iia-study-with-oncolytic-virus-as-planned-following-safety-review-in-cohort-3 https://www.elicera.com/press-releases/elicera-therapeutics-continues-the-phase-i-iia-carma-study-with-its-car-t-cell-therapy-as-planned-following-the-safety-committee-s-assessment-of-cohort-1 https://www.elicera.com/press-releases/elicera-therapeutics-cso-invited-to-present-at-multiple-scientific-conferences https://www.elicera.com/press-releases/elicera-therapeutics-drug-candidate-elc-100-receives-orphan-drug-designation-in-the-u-s-for-the-treatment-of-pancreatic-neuroendocrine-tumors https://www.elicera.com/press-releases/elicera-therapeutics-enrolls-the-last-patient-in-the-clinical-phase-i-ii-trial-with-oncolytic-virus-elc-100 https://www.elicera.com/press-releases/elicera-therapeutics-enters-a-material-transfer-agreement-with-university-hospital-tubingen-for-testing-of-the-company-s-oncolytic-virus-candidates-elc-100-and-elc-201 https://www.elicera.com/press-releases/elicera-therapeutics-enters-a-preclinical-collaboration-agreement-with-china-medical-university-for-the-development-of-elc-201 https://www.elicera.com/press-releases/elicera-therapeutics-enters-agreement-with-biontech-for-contract-manufacturing-of-viral-vectors-for-car-t-cell-therapy https://www.elicera.com/press-releases/elicera-therapeutics-enters-first-international-collaboration-involving-the-itank-platform-with-a-spanish-research-institution https://www.elicera.com/press-releases/elicera-therapeutics-enters-into-agreement-with-baylor-college-of-medicine-for-contract-manufacturing-of-next-generation-oncolytic-virus-elc-201 https://www.elicera.com/press-releases/elicera-therapeutics-files-a-patent-application-for-the-development-of-the-next-generation-oncolytic-viruses https://www.elicera.com/press-releases/elicera-therapeutics-first-day-to-subscribe-ahead-of-the-listing-at-nasdaq-first-north-growth-market https://www.elicera.com/press-releases/elicera-therapeutics-has-been-approved-for-listing-on-nasdaq-first-north-growth-market https://www.elicera.com/press-releases/elicera-therapeutics-has-secured-100-percent-of-the-warrants-of-series-to2-corresponding-to-approximately-sek-22-0-million https://www.elicera.com/press-releases/elicera-therapeutics-hires-erik-penser-bank-as-market-maker https://www.elicera.com/press-releases/elicera-therapeutics-includes-the-first-patient-in-the-phase-i-ii-clinical-study-carma-targeting-b-cell-lymphoma https://www.elicera.com/press-releases/elicera-therapeutics-invitation-to-company-presentation-in-swedish https://www.elicera.com/press-releases/elicera-therapeutics-last-day-to-subscribe-ahead-of-the-listing-at-nasdaq-first-north-growth-market https://www.elicera.com/press-releases/elicera-therapeutics-new-issue-heavily-oversubscribed https://www.elicera.com/press-releases/elicera-therapeutics-participates-in-a-collaborative-project-for-the-development-of-improved-car-t-cell-production-that-has-been-awarded-research-support-of-sek-850-thousand https://www.elicera.com/press-releases/elicera-therapeutics-phd-thesis-describing-the-itank-platform-awarded-best-of-the-year-2021-in-sweden-in-the-field-of-gene-and-cell-therapy https://www.elicera.com/press-releases/elicera-therapeutics-postpones-final-reporting-of-elc-100-study-due-to-database-transition https://www.elicera.com/press-releases/elicera-therapeutics-presents-first-clinical-results-from-itank-armed-car-t-cell-therapy-at-scientific-conference https://www.elicera.com/press-releases/elicera-therapeutics-presents-initial-clinical-data-from-the-carma-study-at-isct-2025-in-new-orleans https://www.elicera.com/press-releases/elicera-therapeutics-presents-preclinical-proof-of-concept-data-for-its-itank-platform-at-the-european-society-of-cell-gene-therapy-congress https://www.elicera.com/press-releases/elicera-therapeutics-provides-update-on-preclinical-car-t-cell-program-elc-401-for-glioblastoma-preclinical-development-concluded-and-clinical-trial-planning-underway https://www.elicera.com/press-releases/elicera-therapeutics-publishes-a-scientific-article-in-nature-communications-about-the-car-t-construct-in-the-elc-401-program https://www.elicera.com/press-releases/elicera-therapeutics-publishes-annual-report-for-2021 https://www.elicera.com/press-releases/elicera-therapeutics-publishes-prospectus-in-connection-with-rights-issue-of-units https://www.elicera.com/press-releases/elicera-therapeutics-publishes-scientific-article-in-nature-biomedical-engineering-on-the-itank-platform-and-data-indicating-its-universal-compatibility-with-other-car-t-cell-therapies https://www.elicera.com/press-releases/elicera-therapeutics-publishes-the-annual-report-for-2022 https://www.elicera.com/press-releases/elicera-therapeutics-publishes-the-annual-report-for-2023 https://www.elicera.com/press-releases/elicera-therapeutics-receives-2-5-million-euros-in-eu-funding-to-fully-finance-a-clinical-phase-i-ii-trial-with-its-car-t-cell-therapy-elc-301-2 https://www.elicera.com/press-releases/elicera-therapeutics-receives-additional-subscription-commitments-from-the-board-and-management-in-the-ongoing-rights-issue https://www.elicera.com/press-releases/elicera-therapeutics-receives-approval-to-initiate-clinical-phase-i-ii-study-carma-with-car-t-cell-therapy-elc-301-in-b-cell-lymphoma https://www.elicera.com/press-releases/elicera-therapeutics-receives-atmp-classification-from-ema-for-oncolytic-virus https://www.elicera.com/press-releases/elicera-therapeutics-receives-conditional-approval-from-the-medical-products-agency-on-its-car-t-cell-clinical-trial-application-to-test-elc-301-carma-study https://www.elicera.com/press-releases/elicera-therapeutics-receives-notice-of-allowance-for-chinease-patent-protecting-the-itank-platform https://www.elicera.com/press-releases/elicera-therapeutics-receives-notice-of-allowance-for-european-patent-protecting-the-itank-tm-platform https://www.elicera.com/press-releases/elicera-therapeutics-receives-notice-of-allowance-for-japanease-patent-protecting-the-elc-401-car-t-cell-candidate https://www.elicera.com/press-releases/elicera-therapeutics-receives-notification-of-partial-payment-of-eur-500-000-from-the-european-innovation-council-accelerator-programme https://www.elicera.com/press-releases/elicera-therapeutics-recruits-cfo https://www.elicera.com/press-releases/elicera-therapeutics-recruits-lifesci-consulting-as-transaction-advisor-to-assist-the-company-in-evaluating-strategic-partnering-initiatives-2 https://www.elicera.com/press-releases/elicera-therapeutics-reports-additional-signals-of-clinical-activity-in-patients-treated-for-neuroendocrine-tumors-in-the-elc-100-study-at-the-oncolytic-virotherapy-summit-in-boston https://www.elicera.com/press-releases/elicera-therapeutics-reports-complete-metabolic-response-cmr-and-well-tolerated-treatment-in-first-two-patients-of-cohort-3-in-carma-study-bringing-total-cmr-to-6-out-of-8-treated-patients https://www.elicera.com/press-releases/elicera-therapeutics-resolves-on-a-compensation-issue-to-underwriters-in-connection-with-the-completed-exercise-period-for-warrants-of-series-to2 https://www.elicera.com/press-releases/elicera-therapeutics-secures-5-million-sek-in-funding-from-vinnova-to-develop-an-automated-car-t-cell-manufacturing-process https://www.elicera.com/press-releases/elicera-therapeutics-strengthens-ip-protection-for-elc-100-through-acquisition-of-patent-from-immunicum https://www.elicera.com/press-releases/elicera-therapeutics-submits-clinical-trial-application-to-evaluate-its-car-t-cell-therapy-in-b-cell-lymphoma https://www.elicera.com/press-releases/elicera-therapeutics-submits-gmp-validation-data-to-the-swedish-medical-products-agency-for-the-carma-study-to-supplement-the-conditionally-approved-clinical-trial-application https://www.elicera.com/press-releases/elicera-therapeutics-successfully-concludes-preclinical-proof-of-concept-studies-for-oncolytic-virus-elc-201-confirming-the-proposed-mode-of-action https://www.elicera.com/press-releases/elicera-therapeutics-to-present-ipdated-carma-study-data-on-march-6-2026-at-the-10th-zurich-immuno-oncology-conference https://www.elicera.com/press-releases/elicera-therapeutics-warrants-to1-are-listed-on-first-north-growth-market https://www.elicera.com/press-releases/elicera-therapeutics-will-participate-in-upcoming-industry-and-investor-conferences-during-the-fall-2 https://www.elicera.com/press-releases/elicera-therapeutics-will-present-the-itank-platform-orally-at-esgct-collaborative-virtual-congress-and-pegs-europe https://www.elicera.com/press-releases/eliceras-ceo-jamal-el-mosleh-recognized-on-in-vivos-list-of-30-rising-leaders-across-the-biopharma-medtech-and-health-technology-sectors https://www.elicera.com/press-releases/erik-penser-bank-initiates-coverage-on-elicera-therapeutics https://www.elicera.com/press-releases/financial-times-writes-about-elicera https://www.elicera.com/press-releases/funding-by-the-swedish-cancer-society https://www.elicera.com/press-releases/funding-from-the-sjoberg-foundation https://www.elicera.com/press-releases/gunilla-enblad-advisor-to-elicera-therapeutics-and-mats-hellstrom-appear-in-unt-to-talk-about-the-carma-trial https://www.elicera.com/press-releases/immunicum-ab-acquires-a-patent https://www.elicera.com/press-releases/immuno-oncology-news-writes-about-eliceras-car-t-cell-program https://www.elicera.com/press-releases/interim-report-elicera-therapeutics-ab-january-june-2021 https://www.elicera.com/press-releases/interview-and-summary-of-2021-in-biostock https://www.elicera.com/press-releases/interviews-with-magnus-essand-and-gunilla-enblad-at-swecarnets-education-day-april-27 https://www.elicera.com/press-releases/lifescientist-interviews-di-yu https://www.elicera.com/press-releases/nomination-committee-for-elicera-therapeutics-appointed https://www.elicera.com/press-releases/nomination-committee-for-elicera-therapeutics-appointed-7 https://www.elicera.com/press-releases/nomination-committee-for-elicera-therapeutics-appointed-a223e https://www.elicera.com/press-releases/nomination-committee-proposes-cmc-specialist-to-elicera-s-board-of-directors https://www.elicera.com/press-releases/nordic-life-science-news https://www.elicera.com/press-releases/nordic-life-science-news-writes-about-eliceras-patent-acquisition-from-immunicum https://www.elicera.com/press-releases/nordic-life-science-news-writes-about-the-itank-publication https://www.elicera.com/press-releases/notice-of-extraordinary-general-meeting-in-elicera-therapeutics-ab https://www.elicera.com/press-releases/oncology-in-sweden-publishes-an-article-by-magnus-essand-on-eliceras-itank-platform-and-upcoming-clinical-study https://www.elicera.com/press-releases/status-update-by-uppsala-university-on-the-clinical-phase-i-ii-study-in-net https://www.elicera.com/press-releases/successful-crowdfunding https://www.elicera.com/press-releases/successfull-collaborative-project-with-drug-development-and-discovery-platform-ddd-at-scilifelab-completed https://www.elicera.com/press-releases/swedish-public-radio-interviews-professor-magnus-essand https://www.elicera.com/press-releases/the-exercise-price-for-the-warrants-of-series-to2-in-elicera-therapeutics-has-been-determined-to-sek-1-85 https://www.elicera.com/press-releases/the-last-day-of-trading-with-the-warrants-of-series-to2-in-elicera-therapeutics-is-today-march-7-2025 https://www.elicera.com/press-releases/the-medical-journal-writes-about-a-clinical-study https://www.elicera.com/press-releases/the-nomination-committee-for-elicera-therapeutics-proposes-re-election-of-board https://www.elicera.com/press-releases/the-subscription-period-in-elicera-therapeutics-rights-issue-of-units-starts-today https://www.elicera.com/press-releases/upsala-nya-tidning-writes-about-eliceras-research-and-upcoming-clinical-studies https://www.elicera.com/press-releases/warrants-of-series-to2-in-elicera-therapeutics-ab-were-subscribed-to-approximately-96-3-percent-and-the-company-resolves-on-a-directed-issue-to-underwriters https://www.elicera.com/press-releases-sv/artikel-i-forskning-och-framsteg https://www.elicera.com/press-releases-sv/beviljad-finansiering-av-sjobergstiftelsen https://www.elicera.com/press-releases-sv/biostock-skriver-om-elicera-och-car-t-celler https://www.elicera.com/press-releases-sv/biostock-video-intervjuar-cso-magnus-essand-om-itank-publikationen https://www.elicera.com/press-releases-sv/bokslutskommunike-2020 https://www.elicera.com/press-releases-sv/ceo-interview-by-nyhetsbyran-direkt https://www.elicera.com/press-releases-sv/daily-mail-skriver-om-elicera https://www.elicera.com/press-releases-sv/delarsbokslut-elicera-therapeutics-ab-januari-juni-2021 https://www.elicera.com/press-releases-sv/delarsbokslut-elicera-therapeutics-ab-januari-mars-2021 https://www.elicera.com/press-releases-sv/di-yu-tilldelas-goran-gustavssonpriset https://www.elicera.com/press-releases-sv/elicera-bjuder-in-till-investerartraffar-28-och-29-februari-2024 https://www.elicera.com/press-releases-sv/elicera-in-nordic-life-science https://www.elicera.com/press-releases-sv/elicera-ingar-avtal-med-framstaende-amerikanskt-cancercenter-for-att-utvardera-anvandningen-av-itank-i-t-cellsreceptorterapier https://www.elicera.com/press-releases-sv/elicera-klargor-status-for-patentansokan-av-itank-plattformen-i-usa https://www.elicera.com/press-releases-sv/elicera-rapporterar-aktiv-lymfom-borta-hos-tva-av-tre-patienter-i-forsta-kohorten-i-carma-studien-med-itank-bevapnad-car-t-cellsterapi https://www.elicera.com/press-releases-sv/elicera-rapporterar-komplett-metabolisk-respons-hos-4-av-6-patienter-i-de-forsta-tva-lagdoskohorterna-i-carma-studien-med-itank-bevapnad-car-t-cellsterapi https://www.elicera.com/press-releases-sv/elicera-rekryterar-cfo https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-byter-certified-adviser-och-likviditetsgarant-till-carnegie-investment-bank-ab-publ https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-byter-certified-adviser-och-likviditetsgarant-till-mangold-fondkommission-ab https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-kallar-till-arsstamma-26-april-2021 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-bokslutskommunike-1-januari---31-december-2023 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-bokslutskommunike-1-januari---31-december-2024 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-bokslutskommunike-1-januari---31-december-2025 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-bokslutskommunike-1-januari-31-december-2021 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-bokslutskommunike-1-januari-31-december-2022 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-byter-certified-adviser-och-likviditetsgarant-till-dnb-carnegie-investment-bank-ab-publ https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsbokslut-1-januari---31-mars-2026 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari---30-juni-2024 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari---30-juni-2025 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari---30-september-2024 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari---30-september-2025 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari---31-mars-2024 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari---31-mars-2025 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari-30-juni-2022 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari-30-juni-2023 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari-30-september-2021 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari-30-september-2022 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari-30-september-2023 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari-31-mars-2022 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publ-delarsrapport-1-januari-31-mars-2023 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ab-publicerar-arsredovisningen-for-2020 https://www.elicera.com/press-releases-sv/elicera-therapeutics-abstract-om-itank-plattformens-potential-att-forstarka-car-t-cellbehandling-av-solida-tumorer-accepterad-for-presentation-pa-isct-2024 https://www.elicera.com/press-releases-sv/elicera-therapeutics-avslutar-framgangsrikt-prekliniska-proof-of-concept-studier-som-bekraftar-verkningsmekanismen-for-det-onkolytiska-viruset-elc-201 https://www.elicera.com/press-releases-sv/elicera-therapeutics-beslutar-om-ersattningsemission-till-garanter-i-samband-med-att-nyttjandeperioden-for-teckningsoptioner-av-serie-to2-lopt-ut https://www.elicera.com/press-releases-sv/elicera-therapeutics-bjuder-in-till-digital-investerartraff-den-4-mars-2025-och-presenterar-pa-life-science-dagen-i-goteborg-den-5-mars-2025 https://www.elicera.com/press-releases-sv/elicera-therapeutics-bjuder-in-till-foretagspresentation https://www.elicera.com/press-releases-sv/elicera-therapeutics-byter-certified-adviser-till-erik-penser-bank-ab https://www.elicera.com/press-releases-sv/elicera-therapeutics-cso-inbjuden-att-presentera-pa-flera-vetenskapliga-konferenser https://www.elicera.com/press-releases-sv/elicera-therapeutics-deltar-i-ett-samarbetsprojekt-for-utveckling-av-forbattrad-car-t-cellstillverkning-som-tilldelats-forskningsstod-om-850-tsek https://www.elicera.com/press-releases-sv/elicera-therapeutics-deltar-vid-kommande-bransch--och-investerarkonferenser-under-hosten https://www.elicera.com/press-releases-sv/elicera-therapeutics-doktorsavhandling-som-beskriver-itank-plattformen-utsedd-till-arets-basta-i-sverige-inom-forskningsfaltet-gen-och-cellterapi-for-2021 https://www.elicera.com/press-releases-sv/elicera-therapeutics-emission-kraftigt-overtecknad https://www.elicera.com/press-releases-sv/elicera-therapeutics-erhaller-atmp-klassificering-av-ema-for-onkolytiskt-virus https://www.elicera.com/press-releases-sv/elicera-therapeutics-erhaller-besked-om-delutbetalning-om-eur-500-000-fran-european-innovation-council-accelerator-programme https://www.elicera.com/press-releases-sv/elicera-therapeutics-erhaller-godkannande-att-initiera-den-kliniska-fas-i-ii-studien-carma-med-car-t-cellsterapin-elc-301-i-b-cellslymfom https://www.elicera.com/press-releases-sv/elicera-therapeutics-erhaller-utokade-teckningsataganden-fran-styrelse-och-ledning-i-den-pagaende-foretradesemissionen https://www.elicera.com/press-releases-sv/elicera-therapeutics-erhaller-villkorat-godkannande-fran-lakemedelsverket-for-ansokan-om-klinisk-provning-carma-studien-med-car-t-cellsterapin-elc-301 https://www.elicera.com/press-releases-sv/elicera-therapeutics-far-besked-om-beviljande-av-europeiskt-patent-som-skyddar-itank-tm-plattformen https://www.elicera.com/press-releases-sv/elicera-therapeutics-far-besked-om-beviljande-av-japanskt-patent-som-skyddar-car-t-cellskandidaten-elc-401 https://www.elicera.com/press-releases-sv/elicera-therapeutics-far-besked-om-beviljande-av-kinesiskt-patent-som-skyddar-itank-plattformen https://www.elicera.com/press-releases-sv/elicera-therapeutics-forskningschef-inbjuden-att-tala-pa-swedish-cancer-research-meeting-2025-den-22-maj https://www.elicera.com/press-releases-sv/elicera-therapeutics-forskningschef-magnus-essand-utses-till-arets-cancerforskare-2026-av-cancerfonden https://www.elicera.com/press-releases-sv/elicera-therapeutics-forskningschef-professor-magnus-essand-skall-halla-en-presentation-pa-swecarnets-utbildningsdag-2022 https://www.elicera.com/press-releases-sv/elicera-therapeutics-fortsatter-fas-i-iia-studien-carma-med-car-t-cellsterapi-som-planerat-efter-sakerhetskommittens-bedomning-i-kohort-1 https://www.elicera.com/press-releases-sv/elicera-therapeutics-fortsatter-fas-i-iia-studien-carma-med-car-t-cellsterapi-som-planerat-efter-sakerhetskommittens-bedomning-i-kohort-2 https://www.elicera.com/press-releases-sv/elicera-therapeutics-fortsatter-fas-i-iia-studien-med-onkolytiskt-virus-som-planerat-efter-sakerhetskommittens-bedomning-i-kohort-3 https://www.elicera.com/press-releases-sv/elicera-therapeutics-genomfor-en-foretradesemission-om-cirka-72-8-msek https://www.elicera.com/press-releases-sv/elicera-therapeutics-genomfor-overtecknad-nyemission-och-lanserar-immunonkologiverksamhet-med-fokus-pa-car-t-celler-och-onkolytiska-virus https://www.elicera.com/press-releases-sv/elicera-therapeutics-genomfor-overtecknad-nyemission-och-sakrar-13-2-msek-i-finansiering https://www.elicera.com/press-releases-sv/elicera-therapeutics-ger-uppdatering-om-det-prekliniska-car-t-cellsprogrammet-elc-401-for-glioblastom-preklinisk-utveckling-avslutad-och-planering-for-klinisk-provning-pagar https://www.elicera.com/press-releases-sv/elicera-therapeutics-har-godkants-for-notering-pa-nasdaq-first-north-growth-market https://www.elicera.com/press-releases-sv/elicera-therapeutics-har-sakerstallt-100-procent-av-teckningsoptionerna-av-serie-to2-om-cirka-22-0-msek https://www.elicera.com/press-releases-sv/elicera-therapeutics-ingar-avtal-om-likviditetsgaranti-med-erik-penser-bank https://www.elicera.com/press-releases-sv/elicera-therapeutics-ingar-materialoverforingsavtal-med-tubingen-universitetssjukhus-for-test-av-bolagets-onkolytiska-viruskandidater-elc-100-och-elc-201 https://www.elicera.com/press-releases-sv/elicera-therapeutics-ingar-prekliniskt-samarbetsavtal-med-china-medical-university-for-utvecklingen-av-elc-201 https://www.elicera.com/press-releases-sv/elicera-therapeutics-inkluderar-den-sista-patienten-i-den-kliniska-fas-i-ii-studien-med-onkolytiska-viruset-elc-100 https://www.elicera.com/press-releases-sv/elicera-therapeutics-inkluderar-forsta-patienten-i-den-kliniska-fas-i-ii-studien-carma-mot-b-cellslymfom https://www.elicera.com/press-releases-sv/elicera-therapeutics-kommer-presentera-itank-plattformen-muntligt-pa-esgct-collaborative-virtual-congress-och-pegs-europe https://www.elicera.com/press-releases-sv/elicera-therapeutics-lakemedelskandidat-elc-100-erhaller-orphan-drug-designation-i-usa-for-behandling-av-neuroendokrina-tumorer-i-bukspottkorteln https://www.elicera.com/press-releases-sv/elicera-therapeutics-lamnar-in-ansokan-om-klinisk-provning-for-att-utvardera-sin-car-t-cellsterapi-vid-behandling-av-b-cellslymfom https://www.elicera.com/press-releases-sv/elicera-therapeutics-lamnar-in-gmp-valideringsdata-till-lakemedelsverket-for-carma-studien-i-syfte-att-komplettera-den-villkorat-godkanda-kliniska-provningsansokan https://www.elicera.com/press-releases-sv/elicera-therapeutics-lamnar-in-patentansokan-for-utveckling-av-nasta-generations-onkolytiska-virus https://www.elicera.com/press-releases-sv/elicera-therapeutics-meddelar-att-abstrakt-accepterats-vid-isct-2026-dublin-komplett-metabolisk-respons-uppnadd-hos-fyra-av-sex-patienter-med-itank-forstarkt-elc-301-i-carma-lymfomstudien https://www.elicera.com/press-releases-sv/elicera-therapeutics-meddelar-att-cancerfonden-beviljat-professor-magnus-essand-vid-uppsala-universitetet-7-5-msek-i-bidrag-for-car-t-cellsforskning https://www.elicera.com/press-releases-sv/elicera-therapeutics-meddelar-att-cancerfonden-tilldelar-senior-investigator-award-till-utvecklingschefen-di-yu https://www.elicera.com/press-releases-sv/elicera-therapeutics-meddelar-deltagande-pa-flertalet-industri-och-partneringkonferenser https://www.elicera.com/press-releases-sv/elicera-therapeutics-meddelar-nasta-sakerhetsuppdatering-i-fas-i-ii-studien-med-elc-100 https://www.elicera.com/press-releases-sv/elicera-therapeutics-meddelar-sista-dag-for-handel-i-btu-och-forsta-dag-for-handel-i-teckningsoptioner-serie-to2 https://www.elicera.com/press-releases-sv/elicera-therapeutics-meddelar-slutgiltiga-data-fran-sin-fas-i-iia-studie-som-visar-en-gynnsam-sakerhetsprofil-och-lovande-tecken-pa-effekt-for-onkolytiska-viruset-elc-100-i-neuroendokrina-tumorer https://www.elicera.com/press-releases-sv/elicera-therapeutics-medgrundare-far-anslag-pa-totalt-4-8-msek-fran-barncancerfonden-for-att-stodja-car-t-forskning-2 https://www.elicera.com/press-releases-sv/elicera-therapeutics-medgrundare-far-ytterligare-bidrag-pa-totalt-7-65-msek-fran-cancerfonden-for-att-stodja-car-t-forskning https://www.elicera.com/press-releases-sv/elicera-therapeutics-medgrundare-magnus-essand-inbjuden-att-presentera-bolagets-car-t-cellsprojekt-vid-varldens-storsta-konferens-om-cancerimmunterapi-cicon https://www.elicera.com/press-releases-sv/elicera-therapeutics-offentliggor-prospekt-i-samband-med-foretradesemission-av-units https://www.elicera.com/press-releases-sv/elicera-therapeutics-offentliggor-styrelsens-beslut-om-emission-av-units-infor-notering-samt-av-finansinspektionen-godkant-prospekt https://www.elicera.com/press-releases-sv/elicera-therapeutics-offentliggor-utfall-i-foretradesemissionen https://www.elicera.com/press-releases-sv/elicera-therapeutics-presenterar-de-forsta-kliniska-resultaten-fran-itank-bevapnad-car-t-cellsbehandling-vid-vetenskaplig-konferens https://www.elicera.com/press-releases-sv/elicera-therapeutics-presenterar-initiala-kliniska-data-fran-carma-studien-vid-isct-2025-i-new-orleans https://www.elicera.com/press-releases-sv/elicera-therapeutics-presenterar-preklinisk-proof-of-concept-data-for-itank-plattformen-pa-european-society-of-gene-cell-therapy https://www.elicera.com/press-releases-sv/elicera-therapeutics-presenterar-uppdaterade-data-fran-carma-studien-den-6-mars-2026-pa-10th-zurich-immuno-oncology-conference https://www.elicera.com/press-releases-sv/elicera-therapeutics-presenteras-pa-life-sciencedagen-i-goteborg-den-6-mars https://www.elicera.com/press-releases-sv/elicera-therapeutics-publicerar-arsredovisning-2021 https://www.elicera.com/press-releases-sv/elicera-therapeutics-publicerar-arsredovisningen-for-2022 https://www.elicera.com/press-releases-sv/elicera-therapeutics-publicerar-arsredovisningen-for-2023 https://www.elicera.com/press-releases-sv/elicera-therapeutics-publicerar-arsredovisningen-for-2024 https://www.elicera.com/press-releases-sv/elicera-therapeutics-publicerar-en-vetenskaplig-artikel-i-nature-biomedical-engineering-om-itank-plattformen-och-data-som-indikerar-dess-universella-kompatibilitet-med-andra-car-t-cellsterapier https://www.elicera.com/press-releases-sv/elicera-therapeutics-publicerar-en-vetenskaplig-artikel-i-nature-communications-om-car-t-konstruktionen-i-elc-401 https://www.elicera.com/press-releases-sv/elicera-therapeutics-rapporterar-fullstandig-metabol-respons-cmr-under-god-sakerhet-hos-de-tva-forsta-patienterna-i-kohort-3-i-carma-studien-vilket-ger-totalt-6-av-8-behandlade-patienter-med-cmr https://www.elicera.com/press-releases-sv/elicera-therapeutics-redovisar-ytterligare-signaler-pa-klinisk-aktivitet-fran-patienter-med-neuroendokrina-tumorer-i-studien-med-elc-100-vid-oncolytic-virotherapy-summit-i-boston https://www.elicera.com/press-releases-sv/elicera-therapeutics-rekryterar-cfo https://www.elicera.com/press-releases-sv/elicera-therapeutics-rekryterar-lifesci-consulting-som-transaktionsradgivare-for-att-bista-foretaget-med-att-utvardera-strategiska-partnerskapsinitiativ-2 https://www.elicera.com/press-releases-sv/elicera-therapeutics-sakrar-5-miljoner-sek-i-bidragsfinansiering-fran-vinnova-for-att-utveckla-en-automatiserad-tillverkningsprocess-av-car-t-celler https://www.elicera.com/press-releases-sv/elicera-therapeutics-skjuter-upp-slutrapportering-av-elc-100-studien-pa-grund-av-databasbyte https://www.elicera.com/press-releases-sv/elicera-therapeutics-sluter-avtal-med-baylor-college-of-medicine-for-kontraktstillverkning-av-nasta-generations-onkolytiska-virus-elc-201 https://www.elicera.com/press-releases-sv/elicera-therapeutics-sluter-avtal-med-biontech-for-kontraktstillverkning-av-virusvektorer-for-car-t-cellsterapi https://www.elicera.com/press-releases-sv/elicera-therapeutics-starker-ip-skyddet-for-elc-100-genom-forvarv-av-patent-fran-immunicum https://www.elicera.com/press-releases-sv/elicera-therapeutics-styrelse-och-ledning-koper-aktier https://www.elicera.com/press-releases-sv/elicera-therapeutics-tecknar-det-forsta-internationella-samarbetsavtalet-kring-itank-plattformen-med-ett-spanskt-forskningsinstitut https://www.elicera.com/press-releases-sv/elicera-therapeutics-teckningsoption-to1-noteras-pa-first-north-growth-market https://www.elicera.com/press-releases-sv/elicera-therapeutics-tilldelas-2-5-miljoner-euro-i-eu-finansiering-for-att-fullt-ut-finansiera-en-klinisk-fas-i-ii-studie-med-sin-car-t-cellsterapi-elc-301-2 https://www.elicera.com/press-releases-sv/elicera-therapeutics-tillkannager-deltagande-pa-flera-bransch-och-investerarmoten-i-oktober-och-november https://www.elicera.com/press-releases-sv/elicera-therapeutics-utser-atmp-experten-karin-hoogendoorn-till-styrelsen https://www.elicera.com/press-releases-sv/elicera-therapeutics-utser-professor-gunilla-enblad-opinionsledare-inom-car-t-celler-och-b-cellslymfom-till-vetenskaplig-radgivare https://www.elicera.com/press-releases-sv/elicera-therapeutics-utser-valberedning https://www.elicera.com/press-releases-sv/elicera-therapeutics-utser-valberedning-4f8eb https://www.elicera.com/press-releases-sv/elicera-therapeutics-utser-valberedning-d https://www.elicera.com/press-releases-sv/elicera-therapeutics-valberedning-foreslar-cmc-specialist-till-styrelsen https://www.elicera.com/press-releases-sv/elicera-therapeutics-valberedning-foreslar-omval-av-styrelsen https://www.elicera.com/press-releases-sv/elicera-therapeutics-valberedning-foreslar-omval-av-styrelsen-f4004 https://www.elicera.com/press-releases-sv/elicera-therapeutics-vd-jamal-el-mosleh-flyttar-sitt-aktieinnehav-i-bolaget-till-kapitalforsakringsdepa https://www.elicera.com/press-releases-sv/elicera-therapeutics-vd-saljer-mindre-del-av-sitt-aktieinnehav---forblir-langsiktig-huvudagare-med-stark-tilltro-till-bolagets-framtid https://www.elicera.com/press-releases-sv/eliceras-styrelse-foreslar-en-foretradesemission-av-units-om-cirka-64-msek https://www.elicera.com/press-releases-sv/eliceras-vd-jamal-el-mosleh-lyfts-fram-i-in-vivos-list-of-30-rising-leaders-i-life-science https://www.elicera.com/press-releases-sv/erik-penser-bank-inleder-bevakning-pa-elicera-therapeutics https://www.elicera.com/press-releases-sv/financial-times-skriver-om-elicera https://www.elicera.com/press-releases-sv/finansiering-fran-cancerfonden https://www.elicera.com/press-releases-sv/foretagspresentation-pa-aktiedagen-goteborg https://www.elicera.com/press-releases-sv/framgangsrikt-samarbetsprojekt-avslutat-med-drug-development-and-discovery-platform-ddd-pa-scilifelab https://www.elicera.com/press-releases-sv/genomford-crowdfunding https://www.elicera.com/press-releases-sv/gunilla-enblad-advisor-to-elicera-therapeutics-and-mats-hellstrom-appear-in-unt-to-talk-about-the-carma-trial https://www.elicera.com/press-releases-sv/idag-inleds-teckningsperioden-for-elicera-therapeutics-nyemission-infor-planerad-listning-pa-nasdaq-first-north-growth-market https://www.elicera.com/press-releases-sv/immunicum-ab-forvarvar-patent https://www.elicera.com/press-releases-sv/immuno-oncology-news-skriver-om-eliceras-car-t-cellsprogram https://www.elicera.com/press-releases-sv/intervju-och-summering-av-2021-i-biostock https://www.elicera.com/press-releases-sv/intervjuer-med-magnus-essand-och-gunilla-enblad-i-samband-med-swecarnets-utbildningsdag-den-27-april https://www.elicera.com/press-releases-sv/kallelse-till-arsstamma-i-elicera-therapeutics-ab-publ https://www.elicera.com/press-releases-sv/kallelse-till-arsstamma-i-elicera-therapeutics-ab-publ-6 https://www.elicera.com/press-releases-sv/kallelse-till-arsstamma-i-elicera-therapeutics-ab-publ-72d73 https://www.elicera.com/press-releases-sv/kallelse-till-arsstamma-i-elicera-therapeutics-ab-publ-efae1 https://www.elicera.com/press-releases-sv/kallelse-till-extra-bolagsstamma-18-mars https://www.elicera.com/press-releases-sv/kallelse-till-extra-bolagsstamma-i-elicera-therapeutics-ab https://www.elicera.com/press-releases-sv/kallelse-till-extra-bolagsstamma-i-elicera-therapeutics-ab-publ https://www.elicera.com/press-releases-sv/kommunike-fran-arsstamma-i-elicera-therapeutics-ab-26-april-2021 https://www.elicera.com/press-releases-sv/kommunike-fran-arsstamma-i-elicera-therapeutics-ab-publ-den-15-maj-2025 https://www.elicera.com/press-releases-sv/kommunike-fran-arsstamma-i-elicera-therapeutics-ab-publ-den-16-maj-2023 https://www.elicera.com/press-releases-sv/kommunike-fran-arsstamma-i-elicera-therapeutics-ab-publ-den-16-maj-2024 https://www.elicera.com/press-releases-sv/kommunike-fran-arsstamma-i-elicera-therapeutics-ab-publ-den-7-mars-2022 https://www.elicera.com/press-releases-sv/kommunike-fran-extra-bolagsstamma-i-elicera-therapeutics-ab https://www.elicera.com/press-releases-sv/kommunike-fran-extra-bolagsstamma-i-elicera-therapeutics-ab-publ-den-20-februari-2024 https://www.elicera.com/press-releases-sv/lakartidningen-skriver-om-klinisk-studie https://www.elicera.com/press-releases-sv/last-day-of-trading-in-unit-rights-in-elicera-therapeutics-rights-issue https://www.elicera.com/press-releases-sv/life-science-sweden-skriver-om-elicera-i-deras-upplaga-om-car-t-cellsterapier https://www.elicera.com/press-releases-sv/lifescientist-intervjuar-di-yu https://www.elicera.com/press-releases-sv/nordic-life-science-news https://www.elicera.com/press-releases-sv/nordic-life-science-news-skriver-om-eliceras-patentforvarv-fran-immunicum https://www.elicera.com/press-releases-sv/nordic-life-science-news-skriver-om-itank-publikationen https://www.elicera.com/press-releases-sv/onkologi-i-sverige-publicerar-en-artikel-av-magnus-essand-om-itank-och-eliceras-kommande-kliniska-studie https://www.elicera.com/press-releases-sv/rattelse-elicera-therapeutics-ab-publ-byter-certified-adviser-och-likviditetsgarant-till-dnb-carnegie-investment-bank-ab-publ https://www.elicera.com/press-releases-sv/rattelse-styrelseledamoter-och-ledande-befattningshavare-nyttjar-teckningsoptioner-av-serie-to2-i-elicera-therapeutics https://www.elicera.com/press-releases-sv/sista-dag-for-handel-med-teckningsoptionerna-av-serie-to2-i-elicera-therapeutics-ar-idag-den-7-mars-2025 https://www.elicera.com/press-releases-sv/sista-dag-for-handel-med-unitratter-i-elicera-therapeutics-foretradesemission https://www.elicera.com/press-releases-sv/sista-dag-for-teckning-i-elicera-therapeutics-nyemission-infor-planerad-listning-pa-nasdaq-first-north-growth-market https://www.elicera.com/press-releases-sv/statusuppdatering-av-uppsala-universitet-kring-den-pagaende-kliniska-fas-i-ii-studien-i-net https://www.elicera.com/press-releases-sv/styrelseledamoter-och-ledande-befattningshavare-nyttjar-teckningsoptioner-av-serie-to2-i-elicera-therapeutics https://www.elicera.com/press-releases-sv/sveriges-radio-intervjuar-professor-magnus-essand https://www.elicera.com/press-releases-sv/teckningskursen-for-nyttjandet-av-teckningsoptioner-av-serie-to2-i-elicera-therapeutics-har-faststallts-till-1-85-sek https://www.elicera.com/press-releases-sv/teckningsoptioner-av-serie-to2-i-elicera-therapeutics-ab-nyttjades-till-cirka-96-3-procent-och-bolaget-genomfor-en-riktad-emission-till-garanter https://www.elicera.com/press-releases-sv/teckningsperioden-i-elicera-therapeutics-foretradesemission-av-units-inleds-idag https://www.elicera.com/press-releases-sv/upsala-nya-tidning-skriver-om-eliceras-forskning-och-kommande-kliniska-forsok https://www.elicera.com/press-releases-sv/valberedningen-foreslar-omval-av-styrelsen-i-elicera-therapeutics